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Abstract: Pancreatic cancer (PC) is known to be frequently associated
with venous thromboembolism (VTE). Although treatment and pro-
phylaxis strategies for VTE in PC patients were updated recently, these
were mainly based on data from Western populations and were not
verified in East Asian ethnic populations.
We investigated the clinical characteristics of VTE in East Asian PC
patients. We reviewed electronic medical records (EMR) of 1334
patients diagnosed with pancreatic adenocarcinoma from 2005 to
2010 at single tertiary hospital in Korea. All the patients with newly
diagnosed VTE were classified by anatomical site and manifestation of
symptoms. The primary outcomes of interest were 2-year cumulative
incidence of VTE events. Cox proportional hazards models were used to
analyze associations between risk factors and clinical outcomes.
A total of 1115 patients were eligible for enrollment. The 2-year
cumulative VTE incidence was 9.2%.Major risk factors associated with
VTE event were advanced cancer stage, major surgery, and poor
performance status. Risk factors associated with mortality after PC
diagnosis included advanced cancer stage, poor performance score,
leukocytosis, and lower albumin level. The overall VTE did not affected
mortality. However in subgroup analysis, symptomatic VTE and deep
vein thrombosis/pulmonary thromboembolism (DVT/PTE) showed
worse prognosis than incidental or intra-abdominal VTE.
The overall incidence of VTE events in Korean PC patients wasnhyeon Cho, MD, D, Ji Hye Lee,
oi, MD, PhD, and Soohyeon Lee, MD, PhD
diagnosis. However, symptomatic VTE and DVT/PTE showed higher
mortality after VTE event.
(Medicine 95(17):e3472)
Abbreviations: ACCP = American college of chest physicians,
AJCC = American Joint Committee on Cancer, ASCO = American
society of clinical oncology, BMI = body mass index, CA19–9 =
cancer antigen 19–9, CI = confidence interval, DVT = deep vein
thrombosis, ECOG = Eastern Cooperative Oncology Group, ESMO
= European society for medical oncology, HR = hazard ratio,
interAD = duration between cancer diagnosis and death (or
censoring), interAK = duration between cancer diagnosis and
VTE event, interKD = duration between VTE event and death (or
censoring), IVC = inferior vena cava, IVT = intra-abdominal
venous thromboembolism, KSSO = Korean Society for the Study
of Obesity, NCCN = national comprehensive cancer network, PTE
= pulmonary thromboembolism, SMV = superior mesenteric vein,
VTE = venous thromboembolism.
INTRODUCTION
A fter Armand Trousseau first reported an associationbetween thrombosis and cancer in 1865, malignancy has
become a well-established risk factor for venous thromboem-
bolism (VTE).1–4 Many studies have reported that cancer
patients have higher tendency to occur VTE than normal
population.5–7 Thrombosis itself is one of the leading cause
of death in cancer patients and at the same time, the antic-
oagulant treatment for VTE can also give rise to bleeding
complications.2,6–11 Thus, the stratification of VTE risk and
prophylactic anticoagulation strategy in cancer patients has
been under debate until recent updates of major international
guidelines. In recent few years, updates of American society of
clinical oncology, National comprehensive cancer network,
American college of chest physicians, and European society
for medical oncology guidelines suggest prophylactic antic-
oagulation to patients with high VTE risk and low bleeding risk
in outpatient chemotherapeutic setting.12–15 These updates
were supported by recent major trials which include PRO-
TECHT, SAVE-ONCO in common cancers and CONKO-
004, FRAGEM-UK in pancreatic cancer (PC).16–19
PC, one of the most lethal malignancies, is known to be
frequently associated with VTE events. Many studies reported
that VTE incidences are different according to cancer type, and
they have a common result that PC is one of the malignancies,
which is most highly associated with VTE incidence.20–23 The
latest retrospective studies reported that incidence of VTE in PC30%.24–26 In the most commonly used
hemotherapy-associated thrombosis, PC
‘very high risk’’ group with gastric
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TABLE 1. Patients Characteristics
Overall VTE Cases Observed
Cumulative Incidence of VTE
(Univariate Analysis)
No (%) No (%) 6 months (%) 2-Year (%) P
Patients 1115 (100.0) 132 (11.8) 5.8 9.2 –
Age groups
<65 years (ref) 572 (51.3) 77 (6.9) 5.9 10.5 –
65 years 543 (48.7) 55 (4.9) 5.7 7.9 0.154
Gender
Male (ref) 675 (60.5) 73 (6.5) 4.7 8.2 –
Female 440 (39.5) 57 (5.1) 7.5 10.9 0.077
BMI
UnderWt (<18.5) 142 (12.7) 15 (1.3) 3.5 5.6 –
Normal (18.5–22.9) 583 (52.3) 61 (5.5) 5.3 8.2 0.330
OverWt (23–25.9) 200 (17.9) 25 (2.2) 6.0 10.6 0.207
Obese (25) 156 (14.0) 26 (2.3) 9.6 15.4 0.017
ECOG PS
0–1 1043 (93.5) 125 (11.2) 5.9 9.6 –
2 72 (6.5) 7 (0.6) 4.2 4.2 0.134
Primary tumor site
Head (ref) 561 (50.3) 79 (7.1) 6.8 11.2 –
Body 236 (21.2) 26 (2.3) 4.2 7.6 0.127
Tail 317 (28.4) 27 (2.4) 5.4 6.9 0.030
Stage
Resectable (ref) 316 (28.3) 24 (2.2) 2.2 5.7 –
Locally advanced (unresectable) 191 (17.1) 35 (3.1) 6.3 14.1 0.005
Metastatic 608 (54.5) 73 (6.5) 7.6 9.5 0.169
Number of metastatic site
1 (ref) 306 (27.4) 41 (3.7) 8.8 11.8 –
2 302 (27.1) 32 (2.9) 6.3 7.3 0.084
Number of comorbidities
0 (ref) 474 (42.5) 58 (5.2) 5.7 9.3 –
1 359 (32.2) 40 (3.6) 5.3 8.6 0.816
2 281 (25.2) 34 (3.0) 6.8 10.0 0.638
Major surgery
None (ref) 906 (81.3) 101 (9.1) 5.9 8.7 –
Yes 209 (18.7) 31 (2.8) 5.7 11.5 0.066
Chemotherapy ( concurrent RT)
None (ref) 216 (19.4) 16 (1.4) 3.2 3.7 –
Adjuvant only 173 (15.5) 29 (2.6) 6.4 13.3 <0.001
Palliative ( adjuvant) 689 (61.8) 85 (7.6) 6.7 10.3 0.004
Baseline lab
WBC <11,000 (ref) 972 (87.2) 113 (10.1) 5.6 9.4 –
WBC 11,000 136 (12.2) 18 (1.6) 7.4 8.1 0.955
Hb 10 (ref) 1015 (91.0) 121 (10.9) 5.7 9.2 –
Hb< 10 93 (8.3) 10 (0.9) 6.5 9.7 0.965
Platelet< 350k (ref) 941 (84.4) 117 (10.5) 6.1 9.7 –
Platelet 350k 166 (14.9) 14 (1.3) 4.2 6.6 0.325
Albumin 3.5 (ref) 934 (83.8) 113 (10.1) 5.6 9.7 –
Albumin< 3.5 171 (15.3) 18 (1.6) 7.0 7.0 0.346
CA19–9< 450 (ref) 523 (46.9) 58 (5.2) 4.8 8.6 –
CA19–9 450 550 (49.3) 69 (6.2) 6.9 10.0 0.599
HbA1c< 6.5 (ref) 103 (9.2) 13 (1.2) 5.8 8.7 –
HbA1c 6.5 375 (33.6) 37 (3.3) 5.3 7.7 0.631
BMI¼ body mass index, CA19–9¼ cancer antigen 19–9, ECOG¼Eastern Cooperative Oncology Group, HbA1c¼ hemoglobin A1c,
VTE¼ venous thromboembolism, WBC¼white blood cell ¼ leukocyte.
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TABLE 2. Anatomical Distribution of VTE
Indicental
No (%)
Symptomatic
No (%)
Overall
No (%)
DVT/PTE 22 (16.7) 33 (25.0) 55 (41.7)
PTE (DVT) 12 26 38
DVT without PTE 10 7 17
Other IVT 73 (55.3) 4 (3.0) 77 (58.3)
Portal vein 36 (27.3) 3 (2.3) 39 (29.5)
Splenic vein 19 (14.4) 0 (0.0) 19 (14.4)
SMV 7 (5.3) 1 (0.8) 8 (6.1)
IMV 5 (3.8) 0 (0.0) 5 (3.8)
Hepatic vein 4 (3.0) 0 (0.0) 4 (3.0)
Gonadal vein 2 (1.5) 0 (0.0) 2 (1.5)
Overall VTE 95 (72.0) 37 (28.8) 132 (100.0)
By anatomical distribution and symptom, P< 0.001.
(DVT/PTE)¼ deep vein thrombosis/pulmonary thromboembolism,
IVT¼ intra-abdominal venous thromboembolism, IMV¼ inferior
Medicine  Volume 95, Number 17, April 2016cancer.24 Furthermore, even asymptomatic incidental VTE was
also associated with mortality in PC.27 These findings suggest
that prophylactic anticoagulation should be an important part of
treatment for patients with PC.
However, all the aforementioned trials were conducted
basically in Western ethnic populations. Because the genetic,
somatometric, and dietary differences may impact quite
mesenteric vein, SMV¼ superior mesenteric vein, VTE¼ venous
thromboembolism.significantly on the VTE biology, these ‘‘blanket’’ guidelines
may not be appropriate for all ethnic populations. Actually
one retrospective study, although it is small-sized, showed
TABLE 3. Multivariate Analysis of Risk for VTE
Variables HR 95% CI P
Gender
Male (ref) –
Female 1.38 0.94–2.02 0.095
BMI, No (%)
UnderWt (<18.5) –
Normal (18.5–22.9) 1.23 0.60–2.51 0.566
OverWt (23–25.9) 1.50 0.68–3.28 0.314
Obese (25) 2.15 0.99–4.65 0.051
Primary tumor site, No (%)
Body to tail (ref) –
Head 1.81 1.20–1.71 0.004
Stage, No (%)
Resectable (ref) –
Locally advanced (unresectable) 2.96 1.58–5.57 0.001
Metastatic 3.62 1.91–6.84 < 0.001
Major surgery
None (ref) –
Yes 2.18 1.23–3.85 0.007
Chemotherapy ( concurrent RT)
None (ref) –
Chemotherapy 2.56 1.23–5.33 0.012
BMI¼ bodymass index, CI¼ confidence interval, HR¼ hazard ratio,
RT¼ radiotherapy.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.significantly lower incidence of VTE (5.3%) in East Asian
patients with PC.28 The low incidence of VTE in East
Asians has been reported in other solid malignancies29–31
and the genetic and biological difference associated with
thrombosis has been reported in multiple studies.32–34 In this
context, it would be meaningful to investigate the character-
istics of VTE in East Asian PC patients in large population
cohort study.
Therefore, we conducted a retrospective study to address
the following objects: (1) to analyze the prevalence of VTE in
Korean PC patients, (2) to investigate risk factors associated
with the development of VTE after PC diagnosis, (3) to explore
risk factors associated with mortality in Korean PC patients, and
(4) to analyze the prognosis by subgroups of VTE patients.
METHODS
Patients
We retrospectively reviewed all the electronic medical
records (EMR) of patients diagnosed with PC at Yonsei Uni-
versity Severance Hospital, Seoul, Korea. A total of 1334
patients were detected between January 2005 and December
2010. Among the detected patients, eligible patients were sorted
out by following criteria: (1) patients diagnosed with histologi-
cally proven pancreatic adenocarcinoma, (2) more than 18 years
old, and (3) patients who were followed up more than 2 times on
outpatient clinic or in hospitalization. This study was approved
by the institutional review board of the Severance Hospital,
Seoul, Korea (IRB approval number, 4–2016–0024).
Variables
All the eligible patients were reviewed for demographic
and clinical variables including age, sex, cancer stage, primary
tumor site, number of metastatic site, initial Eastern Coopera-
tive Oncology Group (ECOG) performance status, body mass
index (BMI), initial lab findings, comorbidity, and treatment
modality. The stage of PC was evaluated according to American
Joint Committee on Cancer 7th guideline.35 All the continuous
variables were converted into categorical variables to perform
univariate and multivariate analysis for VTE incidence and
death rate. The cutoff levels of each laboratory value were
basically determined according to relevant studies. The cutoff
levels of leukocyte (11 109/L), hemoglobin (10 g/dL), platelet
(350 109/L) were originated from the Khorana’s predictive
model for VTE in ambulatory PC patients.26 The cutoff level of
albumin (3.5 g/dL) was originated from normal range of serum
albumin level.36 The cutoff level of hemoglobin A1c (HbA1c)
was originated from, 2015 American Diabetes Association
guideline.37 In regard of cancer antigen 19–9 (CA19–9) level,
almost patients had higher level than normal range, and the
previous studies’ cutoff levels vary. Therefore, we exceptively
used median level in our data as a cutoff level of CA19–9.
Because the definitions of overweight and obesity are different
from those of Western population, we applied the different BMI
cutoff level which is recommended by the guideline of Korean
Society for the Study of Obesity.38–40
The date of cancer diagnosis was defined as the date of first
positive pathological confirmation of pancreatic adenocarci-
noma. The date VTE diagnosis was defined the date of VTE
detection by imaging studies regardless of symptomatic or
Venous Thromboembolism in East Asian Pancreatic Cancerincidental. For the date of death, if patient expired in hospital,
the biological death date was used and if not, the patient’s
disqualification date of the Korean National Health Insurance
www.md-journal.com | 3
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analysis was August 15, 2012.
Identification and Classification and
Identification of VTE
Venous thromboembolisms were diagnosed with imaging
modalities including Doppler ultrasonography, computed tom-
ography (CT), or pulmonary angiography, depending on the
anatomical sites. The asymptomatic and incidental VTE on the
regular imaging follow-up was included to the VTE event,
whereas central venous catheter-related VTE and superficial
phlebitis were excluded. Because VTE group means ‘‘new VTE
group,’’ the VTE group only include patients who were detected
VTE after cancer diagnosis. For the patients who were diag-
nosed VTE with PC simultaneously in the first imaging study,
we investigated additional chart review whether there had been
previous imaging study before cancer diagnosis.
By the anatomical sites, we divided the overall VTE events
into two categories: deep vein thrombosis or pulmonary throm-
boembolism (DVT/PTE) and intra-abdominal venous throm-
boembolism (IVT). The DVT/PTE group includes PTE with or
without DVT, and DVT only. The rest VTE events occurred in
the intra-abdominal vessels—portal vein, superior mesenteric
vein (SMV), inferior vena cava (IVC), splenic vein, and
others—were defined as IVT.
Statistical Analyses
The incidence rate per 100 person-years and the cumulat-
ive incidence rates with 95% confidence intervals (CIs) for
thromboembolism and mortality were calculated. Kaplan–
Meier plots were generated to estimate the influence of patients’
various clinical factors, including cancer stage, ECOG perform-
ance status, and the effect of VTE type, on incidence of VTE
and survival. Differences in probability among comparison
cohorts were assessed using the log-rank test. Cox proportional
hazards models were used to analyze the effect of specified risk
factors on outcomes for VTE or death within 2 years of cancer
FIGURE 1. Kaplan–Meier curves of incidence of venous thrombodiagnosis. Analyses were performed using STATA (Version
14.0, Stata Institute, TX) and R (R Foundation for Statistical
Computing, Vienna, Austria).
4 | www.md-journal.comRESULTS
Patient Characteristics
Among 1334 detected patients, a total of 1115 pancreatic
adenocarcinoma patients met the eligibility criteria patients and
219 were excluded because they had an inappropriate histologic
subtype (N¼ 188, other than pancreatic adenocarcinoma) and
loss of follow-up (N¼ 31, visited only a single time on out-
patient clinic). Among 1115 eligible patients, 675 (60.5%) were
men and 572 (51.3%) were 65 years of age or older. The median
age of overall patients was 64.6 with range between 27.5 and
86.8. More than half of patients (54.5%) had metastatic pan-
creatic adenocarcinoma and nearly half of them (27.1%) had
multiple metastatic lesions. A total of 209 (18.7%) patients
underwent major abdominal surgery with the aim of curative
treatment and 852 (77.3%) received chemotherapy with adju-
vant or palliative aims (Table 1).
Anatomical Distribution of VTE
Divided overall 132 patients as anatomical site, 55 (41.7%)
showed DVT/PTE and 77 (58.3%) showed other IVT. Accord-
ing to the clinical symptom, the symptomatic VTE was 37
(28.8) and incidental VTE was 95 (72.0%). In the DVT/PTE
group, more than half of patients were symptomatic whereas
only 4 patients were symptomatic in IVT group. The 4 sympto-
matic IVT patients included 3 ascites and 1 mesenteric ische-
mia. Table 2 shows a 2 2 table according to symptom and
anatomical site.
Risk Factors for VTE Development
The 2-year cumulative incidence of VTE after cancer
diagnosis was 9.2% and 6-month cumulative incidence was
5.8%. In the univariate analysis, the cancer stage, major surgery,
chemotherapy were associated with higher incidence of VTE.
The BMI level did not show statistically significant association
with VTE incidence, but overweight and obesity showed an
increasing trend with high VTE (Table 1).
bolism, by stage.The 7 patients had VTE and PC simultaneously in the first
imaging study. Two of them had previous CT imaging in the
EMR system, and both had VTE before PC diagnosis. Other five
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Prognostic Factors Influencing OS—Univariate and Multivariate Analysis
Univariate Multivariate
Variables
Median
Survival (month)
95% CI
(month) HR
95%
CI P HR
95%
CI P
Overall patients 9.4 8.8–9.9
Age groups, No (%)
<65 years (ref) 9.8 9.0–10.9 – –
65 years 9.0 8.0–9.7 1.13 0.99–1.28 0.052 1.15 1.01–1.31 0.036
Gender, No (%)
Male (ref) 9.3 8.2–10.2 –
Female 9.5 8.6–10.3 0.92 0.81–1.05 0.201
BMI, No (%)
UnderWt (<18.5) 8.4 6.5–10.2 – –
Normal (18.5–22.9) 9.1 8.0–9.9 0.87 0.72–1.05 0.153 0.96 0.79–1.17 0.704
OverWt (23-25.9) 10.7 9.4–13.5 0.77 0.72–0.97 0.026 0.82 0.64–1.03 0.083
Obese (25) 10.1 8.1–12.8 0.74 0.59–0.95 0.016 0.77 0.61–0.99 0.041
ECOG PS, No (%)
0–1 9.8 9.2–10.5 – –
2 3.8 2.6–4.6 2.54 1.99–3.25 <0.001 1.75 1.34–2.30 <0.001
Stage, No (%)
Resectable (ref) 17.8 15.3–19.7 – –
Locally advanced (unresectable) 13.2 11.8–13.9 1.61 1.33–1.96 <0.001 1.69 1.38–2.07 <0.001
Metastatic 5.7 5.1–6.3 3.51 3.00–4.10 <0.001 3.40 2.88–4.03 <0.001
Baseline lab
WBC< 11,000 (ref) 10.0 9.5–10.9 – –
WBC 11,000 3.4 2.5–4.7 2.15 1.79–2.58 <0.001 1.51 1.24–1.84 <0.001
Hb 10 (ref) 9.7 9.1–10.3 – –
Hb< 10 4.8 3.7–7.2 1.58 1.27–1.97 <0.001 1.24 0.97–1.60 0.089
Albumin 3.5 (ref) 10.1 9.5–11.1 – –
Albumin< 3.5 4.3 3.3–5.4 1.81 1.54–2.15 <0.001 1.60 1.31–1.95 <0.001
CA19–9< 450 (ref) 11.9 10.3–13.1 – –
CA19–9 450 7.3 6.5–8.3 1.59 1.40–1.81 <0.001 1.30 1.14–1.49 <0.001
Venous thromboembolism
No VTE (ref, N¼ 983) 9.3 8.7–9.9 –
overall VTE (N¼ 132) 9.5 7.3–12.4 0.96 0.79–1.16 0.649
symptomatic VTE (N¼ 37) 8.2 6.7–13.1 1.02 0.73–1.42 0.930
incidental VTE (N¼ 95) 9.9 6.7–13.6 0.93 0.75–1.17 0.550
DVT/PE (N¼ 55) 8.0 6.4–12.3 1.04 0.78–1.38 0.795
Other IVT (N¼ 77) 11.3 7.9–14.9 0.91 0.71–1.15 0.425
enc
thro
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CT imaging with PC diagnosis, and we could not evaluate
which diseased between VTE and PC had preceded another one.
Because all the 7 patients did not have evidence of having newly
detected VTE, they were not included to VTE group. Also,
because of too small sample size, we did not consider the 7
patients in modifying statistical analysis.
The results of a multivariable analysis of potential risk
factors associated with developing the VTE are presented in
Table 3. Advanced cancer stage at the time of diagnosis was the
strongest risk factor, with a 3.6-fold higher risk of VTE in
metastatic cancer (hazard ratio (HR)¼ 3.62; 95% CI: 1.91,
6.84; P< 0.001) and 2.9-fold higher in locally advanced cancer
(HR¼ 2.96; 95% CI: 1.58, 5.57; P¼ 0.001) compared with
BMI¼ body mass index, CA19–9¼ cancer antigen 19–9, CI¼ confid
ratio, IVT¼ intra-abdominal venous thromboembolism, VTE¼ venousresectable PC. Major surgery was another risk factor
(HR¼ 2.18; 95% CI: 1.23, 3.85; P¼ 0.007) and chemotherapy
also affected higher VTE incidence (HR¼ 2.56; 95% CI: 1.23,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.5.33; P¼ 0.012). Age, abnormal laboratory value, and number
of comorbidities were not significantly associated with
increased risk of developing VTE. Obesity showed a trend
toward higher VTE incidence but not a significant difference.
Kaplan–Meier plots of the incidence of VTE, stratified by
stage, showed a strong relationship between cancer stage and
VTE incidence (Figure 1).
Risk Factors for Death After TE events
Risk factors predicting death after PC diagnosis, based on
univariate and multivariate analyses, are presented in Table 4.
Overall median survival was 9.4 month. In multivariable
analysis, significant risk factors include metastatic cancer stage
(HR¼ 3.40; 95% CI: 2.88, 4.03; P< 0.001), worse ECOG
e interval, ECOG¼Eastern Cooperative Oncology Group, HR¼ hazard
mboembolism, WBC¼white blood cell.performance status (HR¼ 1.75; 95% CI: 1.34, 2.30;
P< 0.001), leukocytosis (HR¼ 1.51; 95% CI: 1.24, 1.84;
P< 0.001), and lower albumin level (HR¼ 1.60; 95% CI:
www.md-journal.com | 5
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overall VTE nor each subgroup of VTE was predictive factors
for death. Advanced age (HR¼ 1.15; 95% CI: 1.01, 1.31;
P¼ 0.036), high CA19–9 level (HR¼ 1.30; 95% CI: 1.14,
1.49; P< 0.001) were associated with higher death risk. Unlike
VTE risk, higher BMI showed an inverse trend of death risk,
which means that lower BMI was associated with lower
survival rate.
Two Kaplan–Meier survival plots show survival after PC
diagnosis stratified by stage and VTE development (Figure 2).
VTE development did not showed survival difference, whereas
cancer stage affected the patients’ survival definitely.
Subgroup Analysis in VTE Patients
The subgroup analysis was performed by symptom and site
(Figure 3). Symptomatic VTE showed worse prognosis after
VTE event compared with incidental VTE (HR 1.87; 95% CI
1.26, 2.78; P¼ 0.002). DVT/PTE also showed worse prognosis
after VTE event compared with other IVT group (HR 1.53; 95%
CI 1.02, 2.20; P¼ 0.022). These differences were mainly shown
FIGURE 2. Survival after diagnosis of PC, by staging (A) and venoin resectable PC, whereas advanced stage showed less survival
difference by symptom and anatomical sites. (Supplementary
data 4, http://links.lww.com/MD/A930).
FIGURE 3. Survival after venous thromboembolic event by symptom
6 | www.md-journal.comDISCUSSION
This retrospective study is the first attempt to provide a
large population-based analysis of the epidemiology of VTE
among patients with newly diagnosed pancreatic adenocarci-
noma in an East Asian ethnic population. According to this
study, the 2-year cumulative incidence of total VTE events
associated with pancreatic adenocarcinoma in Korean patients
is 9.2%, which is lower than that of Western groups in recently
reported studies.24–26
Apart from overall incidence, our data show several
different characteristics in East Asian ethnics compared with
Western populations. The most important point is, contrary to
previous studies, the VTE event did not affect the overall
survival after cancer diagnosis in patients with PC regardless
of symptom or anatomical site. Although the causative mech-
anism is not clear, we hypothesized that the balance between
aggressiveness of cancer and that of VTE would explain this
difference. Because PC itself is the most aggressive cancer,
relatively less aggressive feature of VTE—the possible charac-
teristics of East Asian population—would not affect the overall
thromboembolism (B).mortality. From the colorectal cancer data of Chew et al,7 we
can infer that the effect of VTE would be less in the advanced
stage. In this study, differences in death incidence were largest
(A) and cancer type (B).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
among patients with loco-regional cancer; no significant differ-
ences were found among patients with metastatic cancer, which
can be explained by our hypothesis that metastatic cancer’s
aggressiveness can dominate the clinical meaning of VTE.
Shaib et al41 also showed that there was no survival difference
between patients with VTE compared with those without VTE
in metastatic PC patients. The similar findings are shown in our
data as Figure 3 and supplementary data 4, http://links.lww.-
com/MD/A930. These data implicate that VTE would have
larger influence on survival in earlier stage of PC, whereas it
would be masked in the more advanced cancer stage. From
these findings, we can hypothesize that the aggressive cases
such as PC or metastatic stage of other cancers would dominate
the VTE aggressiveness and if Asian populations’ VTE is less
aggressive, this imbalance would be accelerated and conceal the
VTE influence.
Our data suggest that the significant risk factors associated
with the development of VTE after PC diagnosis are primary
site, stage, major surgery, and chemotherapy. Unlike other
factors (stage, major surgery, and chemotherapy) which have
been already shown in previous studies,25–27 the tumor site
(pancreatic head) as a risk factor for VTE seems to be unfa-
miliar. We hypothesized that pancreatic head cancer might be
frequently associated with early detection at relatively early
stage because of symptoms and signs such as pain, jaundice, or
Courvoisier’s sign. The tumor site, stage, and chemotherapy
showed minimal degree of multicollinearity, which means they
did not highly affected each other in multivariate analysis.
In regards of symptom and the anatomical site, our data
showed higher proportion of incidental and intra-abdominal
VTE than previous studies. Because incidental and IVT showed
less aggressiveness than symptomatic or DVT/PTE, the pro-
portion would affect the overall prognosis after VTE event. In
the same manner, the symptomatic VTE showed worse progress
than incidental VTE, however all these VTE showed no sig-
nificant difference than non-VTE group. This finding is differ-
ent from the results of Khorana et al.27 We cannot assure this
difference is the East Asian ethnic’s characteristics, but can
suppose that higher proportion of other IVT is the character-
istics of East Asian (Table 2) and that would attribute the ‘‘less
aggressiveness’’ of East Asian ethnics. In summary, VTE event
did not affect survival after PC diagnosis, but anatomical site
and symptom appearance of VTE affected survival after
VTE diagnosis.
About BMI and prognosis in patients with PC, the most
recent two systematic review and meta-analyses showed inter-
esting results. Majumder et al42 showed positive correlation
between obesity and mortality in PC patients in Western but not
Asia-Pacific populations. Ramsey and Martin43 reported that
BMI increases the complexity in resection of PC, but aggressive
para-operative care could mitigate obesity-associated morbidity
and mortality. These two results imply that there is no ‘‘uni-
versally applicable’’ relationship between BMI and prognosis
in PC and the relationship has to be individually evaluated
according to clinical or demographical setting. Our data suggest
that obesity BMI is associated with higher incidence of VTE but
underweight is associated with higher mortality in East Asian’s
PC patients.
The reason why there are several differences between our
data andWestern’s data is still unclear. However, we cautiously
hypothesize that some genetic, biological, somatometric factor
Medicine  Volume 95, Number 17, April 2016would majorly affect this result, not clinical practice pattern
such as less screening tests. That is because in Korean practice,
PC patients take imaging test regularly, and moreover, the study
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.is performed in one of the largest center with public confidence
in South Korea.
The first limitation of this study is that it was conducted at a
single institution. However, Severance Hospital is one of the
biggest volume hospitals in Korea and admits patients from
across the country and we recognize that we can generalize the
entire Korean population. The second limitation is the absence
of detailed information about the use of prophylactic antic-
oagulation. However, in Severance Hospital, there was no
routine prophylactic anticoagulation for chemotherapy or oper-
ation. So, anticoagulant prophylaxis does not have a chance to
be a hidden confounding factor. Third, the impact of anatomical
site and symptom of VTE on survival after VTE event was not
accessed in multivariate analysis because lack of data in the
timing of VTE event. Instead, we only showed Kaplan–Meier
curves in Figure 3. Fourth, because chest CT is not routinely
checked during follow-up period of PC patients, the incidence
of incidental DVT/PTE might be underestimated. However,
there is the same possibility in Western population, because the
follow-up practice is not different between Korean andWestern
hospitals. Because the aim of this study is to compare the VTE
incidence between Korean and other population, the possibility
to underestimate the incidental DVT/PTE could not be a
critical pitfall.
In conclusion, the overall incidence of VTE events in
Korean PC patients was lower than that of Western groups.
The most significant risk factor associated with a new VTE
event and higher mortality was advanced cancer stage. Unlike
Western population, VTE event did not affect overall prognosis.
However, DVT/PTE and symptomatic VTE showed higher
mortality after VTE events than their counterparts, which were
dominant at earlier cancer stage. Future studies are necessary
that explore the link between biological characteristics of East
Asians and lower VTE aggressiveness, and ultimately, the goal
of this study is to be a clue to update of current ‘‘blanket’’
guidelines into more detailed, multi-dimensional, and real-
world guideline.
ACKNOWLEDGMENT
The authors thank the ‘‘E-world Editing’’ for English
proofreading.
REFERENCES
1. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel-Dieu Paris.
1865;3:654–712.
2. Chew HK, Wun T, Harvey D, et al. Incidence of venous
thromboembolism and its effect on survival among patients with
common cancers. Arch Intern Med. 2006;166:458–464.
3. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous
thromboembolism in patients hospitalized with cancer. Am J Med.
2006;119:60–68.
4. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein
thrombosis and pulmonary embolism: a population-based case-
control study. Arch Intern Med. 2000;160:809–815.
5. Heit JA, Spencer FA, White RH. The epidemiology of venous
thromboembolism. J Thromb Thrombolysis. 2016;41:3–14.
6. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a
leading cause of death in cancer patients receiving outpatient
chemotherapy. J Thromb Haemost. 2007;5:632–634.
Venous Thromboembolism in East Asian Pancreatic Cancer7. Chew HK, Wun T, Harvey DJ, et al. Incidence of venous
thromboembolism and the impact on survival in breast cancer
patients. J Clin Oncol. 2007;25:70–76.
www.md-journal.com | 7
8. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in
patients with colorectal cancer: incidence and effect on survival. J
Clin Oncol. 2006;24:1112–1118.
9. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboem-
bolism and anticoagulation on cancer and cancer survival. J Clin
Oncol. 2009;27:4902–4911.
10. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med.
2000;343:1846–1850.
11. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous
thromboembolism and bleeding complications during anticoagulant
treatment in patients with cancer and venous thrombosis. Blood.
2002;100:3484–3488.
12. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembo-
lism prophylaxis and treatment in patients with cancer: American
Society of Clinical Oncology clinical practice guideline update. J
Clin Oncol. 2013;31:2189–2204.
13. National Comprehensive Cancer Network (NCCN) Guideline. Can-
cer-Associated Venous Thromboembolic Disease. (2015) Available
at: http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
Accessed March 31, 2016.
14. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for
VTE disease: antithrombotic therapy and prevention of thrombosis,
9th ed: American College of chest physicians evidence-based clinical
practice guidelines. Chest. 2012;141(2 suppl):e419S–e494S.
15. Mandala M, Falanga A, Roila F. Management of venous throm-
boembolism (VTE) in cancer patients: ESMO clinical practice
guidelines. Ann Oncol. 2011;22(suppl 6):vi85–vi92.
16. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the
prevention of thromboembolic events in ambulatory patients with
metastatic or locally advanced solid cancer receiving chemotherapy:
a randomised, placebo-controlled, double-blind study. Lancet Oncol.
2009;10:943–949.
17. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for
thromboprophylaxis in patients receiving chemotherapy for cancer. N
Engl J Med. 2012;366:601–609.
18. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic
low-molecular weight heparin for ambulatory patients with advanced
pancreatic cancer: outcomes from the CONKO-004 trial. J Clin
Oncol. 2015;33:2028–2034.
19. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus
gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
Eur J Cancer. 2012;48:1283–1292.
20. Marks MA, Engels EA. Venous thromboembolism and cancer risk
among elderly adults in the United States. Cancer Epidemiol
Biomarkers Prev. 2014;23:774–783.
21. Khorana AA, Dala M, Lin J, et al. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer
patients undergoing chemotherapy in the United States. Cancer.
2013;119:648–655.
22. Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk
in patients with cancer receiving chemotherapy: a real-world
analysis. Oncologist. 2013;18:1321–1329.
23. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in
patients with cancer: a systematic review and meta-analysis. PLoS
Med. 2012;9:e1001275.
Lee et al24. Menapace LA, Peterson DR, Berry A, et al. Symptomatic and
incidental thromboembolism are both associated with mortality in
pancreatic cancer. Thromb Haemost. 2011;106:371–378.
8 | www.md-journal.com25. Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and
clinical outcomes in patients with thromboembolic events and
invasive exocrine pancreatic cancer. Cancer. 2012;118:3053–
3061.
26. Munoz Martin AJ, Garcia Alfonso P, Ruperez Blanco AB, et al.
Incidence of venous thromboembolism (VTE) in ambulatory
pancreatic cancer patients receiving chemotherapy and analysis
of Khorana’s predictive model. Clin Trans Oncol. 2014;16:
927–930.
27. Khorana AA, Kuderer NM, Culakova E, et al. Development and
validation of a predictive model for chemotherapy-associated throm-
bosis. Blood. 2008;111:4902–4907.
28. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in
patients with pancreatic adenocarcinoma: lower incidence in Asian
ethnicity. Thromb Res. 2008;122:485–490.
29. Amer MH. Cancer-associated thrombosis: clinical presentation and
survival. Cancer Manag Res. 2013;5:165–178.
30. Keenan CR, White RH. The effects of race/ethnicity and sex on the
risk of venous thromboembolism. Curr Opin Pulm Med.
2007;13:377–383.
31. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc
Med. 2001;1:7–26.
32. Margaglione M, Grandone E. Population genetics of venous
thromboembolism. A narrative review. Thromb Haemost.
2011;105:221–231.
33. Tang L, Hu Y. Ethnic diversity in the genetics of venous
thromboembolism. Thromb Haemost. 2015;114:901–909.
34. Chan SL, Goh BC, Chia KS, et al. Effects of CYP4F2 and GGCX
genetic variants on maintenance warfarin dose in a multi-ethnic
Asian population. Thromb Haemost. 2011;105:1100–1102.
35. American Joint Committee on Cancer (AJCC). Pancreatic Cancer
Staging. 7th ed. 2010:Available at: https://cancerstaging.org/Pages/
default.aspx. Accessed March 31, 2016.
36. Rush University. Normal Range for Common Laboratory Test-
s.2013:Available at: https://web.archive.org/web/20130114222140/
http://www.rush.edu/webapps/rml/RMLRangesCMP.jsp. Accessed
March 31, 2016.
37. American Diabetes Association. Diabetes Management Guideline-
s.2015:Available at: http://www.ndei.org/ADA-diabetes-management-
guidelines-diagnosis-A1C-testing.aspx. Accessed March 31, 2016.
38. World Health Organization (WHO). The Asia-Pacific Perspective:
Redefining Obesity and its Treatment2000:Available at: http://
www.wpro.who.int/nutrition/documents/Redefining_obesity/en/.
Accessed March 31, 2016.
39. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in
Korean men and women. N Engl J Med. 2006;355:779–787.
40. Kim MK, Lee WY, Kang JH, et al. 2014 clinical practice guidelines
for overweight and obesity in Korea. Endocrinol Metab.
2014;29:405–409.
41. Shaib W, Deng Y, Zilterman D, et al. Assessing risk and mortality
of venous thromboembolism in pancreatic cancer patients. Antic-
ancer Res. 2010;30:4261–4264.
42. Majumder K, Gupta A, Arora N, et al. Premorbid obesity and
mortality in patients with pancreatic cancer: a systematic review and
meta-analysis. Clin Gastroenterol Hepatol. 2016;14:355–368.
Medicine  Volume 95, Number 17, April 201643. Ramsey AM, Martin RC. Body mass index and outcomes frompancreatic resection: a review and meta-analysis. J Gastrointest Surg.
2011;15:1633–1642.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
